ISC 2026 | Interdisciplinary collaboration to manage lipoprotein(a) and the associated risks

I think cardiologists are a great group to have in terms of partnership to treat Lp(a) and the Lp(a)-associated risk. Preventive medicine, especially within primary care, is another really good collaborative group. And the importance of engaging the different collaborative specialties is that as a neurologist, you’re going to be focusing on the stroke-specific care post-event. Partnering with preventive cardiology and preventive medicine allows us to help with mitigating some of the other contributing risks, so better treating LDL, coming up with more advanced therapies, helping patients get access to these therapies, which can be sometimes complex depending on insurance and patient comfort with the different types of medicines that are out there. Additionally, preventive cardiologists and preventive medicine can help titrate what the actual goal of treatments should be. In many cases, since we don’t have FDA-approved medications for Lp(a) specifically, this means stricter goals, which may not be as evident or as obvious at first glance in terms of what the LDL and other risk factors should be. So in partnering together, patients are able to achieve those goals faster and maintain a durable level of treatment longer, which overall decreases their risk.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.